التفاصيل البيبلوغرافية
| العنوان: |
Ticagrelor monotherapy after CABG—Probably not at all and definitely not forever. |
| المؤلفون: |
Sandner, Sigrid1 (AUTHOR) sigrid.sandner@meduniwien.ac.at, Redfors, Björn2 (AUTHOR) |
| المصدر: |
Journal of Cardiac Surgery. Jul2022, Vol. 37 Issue 7, p1978-1979. 2p. |
| مستخلص: |
Notably, only 4 new SVG occlusions and 2 new SVG stenoses occurred between years 1 and 2, with no significant differences between the treatment arms ( I p i = .41). The rate of SVG occlusion in the 142 patients who consented to the extended study and underwent imaging at 2 years after CABG did not differ significantly between the treatment groups (ticagrelor 13.2%, aspirin 15.7%, I p i = .71). Keywords: coronary artery bypass; patency; saphenous vein graft; ticagrelor EN coronary artery bypass patency saphenous vein graft ticagrelor 1978 1979 2 06/06/22 20220701 NES 220701 The Ticagrelor Antiplatelet therapy to Reduce Graft Events and Thrombosis (TARGET) trial randomized 250 patients after coronary artery bypass grafting (CABG) to ticagrelor monotherapy or aspirin monotherapy. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
